Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Effects of Darifenacin vs Oxybutynin in Elderly
NCT00170768Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darifenacin in overactive bladder (OAB) (3 arms), sponsored by Novartis. Primary endpoint: Accuracy of delayed recall Name-Face Association Test at 3 weeks. Started Feb 2005; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00170768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170768.